News Release

Date: September 24, 2007 

New UC San Diego Medical Center Urology Chief Is a Leader in Minimally Invasive Robotic Techniques

 

 

Christopher Kane, M.D., F.A.C.S., a nationally recognized researcher and specialist in the diagnosis and treatment of prostate and kidney cancer has been recruited as the new chief of urology at the University of California, San Diego Medical Center and Moores UCSD Cancer Center.

Christopher Kane, M.D.

Christopher Kane, M.D., F.A.C.S.


“Dr. Kane’s recruitment to UC San Diego Medical Center represents the university’s next step in developing a comprehensive world-class cancer center in Southern California,” said Mark A. Talamini, M.D., professor and chair of surgery at UCSD Medical Center. “Chris Kane is a true physician-scientist whose discoveries will be applied at the bedside of our cancer patients, and will lead to better treatment for all patients seeking innovative care options.”

A leader in minimally-invasive surgical techniques such as robotics and laparoscopic procedures, Kane is the former vice chair of urology at the University of California, San Francisco where he was also a member of the UCSF Comprehensive Cancer Center, director of the Urologic Oncology Fellowship, and chief of urology of the Veterans Affairs Medical Center San Francisco. Kane is also a highly decorated Naval Officer, who served as Battalion Surgeon for 3d Battalion, 12th Marine Regiment in Saudi Arabia and Kuwait during Operation Desert Shield and Desert Storm receiving multiple military awards. 

Known for his highly meticulous techniques, Kane brings to the San Diego region extensive experience in advanced surgical robotic procedures that allow him to perform very precise, highly magnified, nerve-sparing operations. He has performed more than 300 robotic prostatectomies, the highest volume of prostate removal surgeries in northern California.

Kane is also an expert in the minimally-invasive treatment of kidney cancer, including laparoscopic nephrectomy and partial nephrectomy, procedures to remove one kidney or part of a kidney. Kane will continue his research at UCSD Medical Center with an in-depth focus on studying and analyzing patient outcomes and on discovering new biologic agents to treat cancer.

Now a resident of Rancho Bernardo, Kane has returned to San Diego where he was once the staff urologist and residency director at the San Diego Naval Medical Center in the late nineties.

“I am thrilled to be back in San Diego and look forward to working with an exceptional team of physicians who are revolutionizing treatments for kidney, bladder, prostate, and testicular diseases,” said Kane. “To each of my patients, I will offer the most advanced surgical techniques, supported by a caring and compassionate approach in every interaction.”

Kane has an undergraduate degree in Mechanical Engineering from the University of California, Davis and received his medical degree from the F. Edward Hebert School of Medicine at the Uniformed Services University of the Health Sciences. He received his General Surgery training at the University of California Davis East Bay Surgery program where he was selected the Outstanding Surgical Intern.  He completed his Urology residency at Oakland Naval Hospital and the Urology Department at UCSF.

Kane has been a principal or co-investigator in numerous clinical trials related to the role of obesity in the reoccurrence of prostate cancer, biopsy information in risk assessment and outcomes, the study of prostate specific antigen, and the impact of ethnicity and socioeconomic status on cancer patients.

Kane has authored or co-authored over 120 publications and book chapters. He is on the Editorial Board of the Journal of Urology, the American Journal of Urology Review and American Journal of Oncology Review.  He is an active member of numerous professional medical societies including the American Urological Association, the American College of Surgeons, the Society of Urologic Oncology, the Society of Endourology and is on the GU Core of the Cancer and Leukemia Group B. 

Prostate cancer is the second most common form of cancer found in males in the United States. Sixteen percent of American men, or one in six male patients, will be diagnosed with the disease during their lifetime. For a large majority of these men, treatment for prostate cancer results in positive outcomes and a return to good health.

###

Media Contact: Jackie Carr, 619-543-6163, jcarr@ucsd.edu